Aspects of early arthritis. Biological therapy in early arthritis - Overtreatment or the way to go?

Arthritis Research and Therapy

Volumn 9, Issue 2, 2007, Pages

  Ikeda, Kei ^a   Cox, Sally ^a   Emery, Paul ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HLA DR ANTIGEN; INFLIXIMAB; METHOTREXATE; PLACEBO; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIRHEUMATIC AGENT;

ARTHRITIS; BONE RADIOGRAPHY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST BENEFIT ANALYSIS; DISEASE ACTIVITY; DISEASE DURATION; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENETIC MARKER; GENOTYPE; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; INFECTION; JOINT INJURY; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSTMARKETING SURVEILLANCE; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT DURATION; TUBERCULOSIS; DRUG ANTAGONISM; DRUG EFFECT; EARLY DIAGNOSIS; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; EARLY DIAGNOSIS; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 36349022620     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2177     Document Type: Review

References (59)

1. Anderson JJ Wells G Verhoeven AC Felson DT Factors predicting response to treatment in rheumatoid arthritis: The importance of disease duration Arthritis Rheum 2000, 43:22-29 10.1002/ 1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9 10643696
2. Emery P Early Arthritis Targeted Therapies in Rheumatology London: Martin Dunitz Smolen JS, Lipsky PE 2003, 509-513
3. Mottonen T Hannonen P Korpela M Nissila M Kautiainen H Ilonen J Laasonen L Kaipiainen-Seppanen O Franzen P Helve T Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis Arthritis Rheum 2002, 46:894-898 10.1002/art.10135 11953964
4. Nell VP Machold KP Eberl G Stamm TA Uffmann M Smolen JS Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis Rheumatology (Oxford) 2004, 43:906-914 10.1093/rheumatology/keh199 15113999
5. van der Heide A Jacobs JW Bijlsma JW Heurkens AH van Booma-Frankfort C van der Veen MJ Haanen HC Hofman DM van Albada-Kuipers GA ter Borg EJ The effectiveness of early treatment with 'second-line' antirheumatic drugs. A randomized, controlled trial Ann Intern Med 1996, 124:699-707 8633829
6. Molenaar ET Voskuyl AE Dinant HJ Bezemer PD Boers M Dijkmans BA Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission Arthritis Rheum 2004, 50:36-42 10.1002/art.11481 14730597
7. Pincus T Ferraccioli G Sokka T Larsen A Rau R Kushner I Wolfe F Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: Updating a 1983 review Rheumatology (Oxford) 2002, 41:1346-1356 10.1093/rheumatology/41.12.1346 12468813
8. van der Heijde DM Joint erosions and patients with early rheumatoid arthritis Br J Rheumatol 1995, 34(Suppl 2):74-78 8535653
9. Firestein GS Pathogenesis of rheumatoid arthritis: How early is early? Arthritis Res Ther 2005, 7:157-159 1175047 15987499 10.1186/ar1780
10. Quinn MA Emery P Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention Clin Exp Rheumatol 2003, 21(5 Suppl 31):S154-S157 14969068
11. Raza K Buckley CE Salmon M Buckley CD Treating very early rheumatoid arthritis Best Pract Res Clin Rheumatol 2006, 20:849-863 16980210 10.1016/j.berh.2006.05.005
12. Maini RN Breedveld FC Kalden JR Smolen JS Davis D Macfarlane JD Antoni C Leeb B Elliott MJ Woody JN Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Arthritis Rheum 1998, 41:1552-1563 10.1002/ 1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W 9751087
13. Maini R St Clair EW Breedveld F Furst D Kalden J Weisman M Smolen J Emery P Harriman G Feldmann M Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group Lancet 1999, 354:1932-1939 10.1016/ S0140-6736(99)05246-0 10622295
14. St Clair EW van der Heijde DM Smolen JS Maini RN Bathon JM Emery P Keystone E Schiff M Kalden JR Wang B Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial Arthritis Rheum 2004, 50:3432-3443 10.1002/art.20568 15529377
15. Smolen J Han C Bala M Van der Heijde D Emery P Bathon JM Keystone E Maini RN Kalden JR Baker D Patients with early rheumatoid arthritis achieved a clinically meaningful and sustained improvement in physical function after treatment with infliximab Ann Rheum Dis 2005, 64(Suppl 3):1365
16. Smolen JS Han C Bala M van der Heijde D Emery P Bathon JM Keystone EC Maini RN Kalden JR Aletaha D Infliximab consistently induces clinical remission in patients with early active rheumatoid arthritis regardless of remission criteria Arthritis Rheum 2005, 52:S139-S139
17. Bathon JM Martin RW Fleischmann RM Tesser JR Schiff MH Keystone EC Genovese MC Wasko MC Moreland LW Weaver AL A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis N Engl J Med 2000, 343:1586-1593 10.1056/NEJM200011303432201 11096165
18. Breedveld FC Weisman MH Kavanaugh AF Cohen SB Pavelka K van Vollenhoven R Sharp J Perez JL Spencer-Green GT The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment Arthritis Rheum 2006, 54:26-37 10.1002/art.21519 16385520
19. Genovese MC Bathon JM Martin RW Fleischmann RM Tesser JR Schiff MH Keystone EC Wasko MC Moreland LW Weaver AL Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes Arthritis Rheum 2002, 46:1443-1450 10.1002/art.10308 12115173
20. Emery P Genovese MC Kavanaugh AF Cohen SB Perez JL Sasso EH Adalimumab plus methotrexate results in less frequent and less severe radiographic progression than methotrexate alone at all levels of clinical response in early rheumatoid arthritis Ann Rheum Dis 2006, 65(Suppl 2):88
21. Smolen JS Van Der Heijde DM St Clair EW Emery P Bathon JM Keystone E Maini RN Kalden JR Schiff M Baker D Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial Arthritis Rheum 2006, 54:702-710 10.1002/art.21678 16508926
22. Smolen JS Han C Bala M Maini RN Kalden JR van der Heijde D Breedveld FC Furst DE Lipsky PE Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study Arthritis Rheum 2005, 52:1020-1030 10.1002/art.20982 15818697
23. Lam J Takeshita S Barker JE Kanagawa O Ross FP Teitelbaum SL TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand J Clin Invest 2000, 106:1481-1488 387259 11120755
24. Redlich K Hayer S Ricci R David JP Tohidast-Akrad M Kollias G Steiner G Smolen JS Wagner EF Schett G Osteoclasts are essential for TNF-α-mediated joint destruction J Clin Invest 2002, 110:1419-1427 151809 12438440 10.1172/JCI200215582
25. Diarra D Stolina M Polzer K Zwerina J Ominsky MS Dwyer D Korb A Smolen J Hoffmann M Scheinecker C Dickkopf-1 is a master regulator of joint remodeling Nat Med 2007, 13:156-163 10.1038/nm1538 17237793
26. Buch MH Bingham SJ Bejarano V White J Emery P Do patients with rheumatoid arthritis demonstrate an improvement on etanercept following an inadequate response to infliximab? Arthritis Rheum 2003, 48(Suppl):325 10.1002/art.10784
27. Furst D Yocum D Weisman M Troum O Bray V Wallace D Gaylis N Ritter J Yeilding N Gilmer K Infliximab provides additional clinical and radiographic benefits in RA patients who have an inadequate response to etanercept Ann Rheum Dis 2005, 64(Suppl 3):1391 10.1136/ard.2005.044941
28. van Vollenhoven R Harju A Brannemark S Klareskog L Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense Ann Rheum Dis 2003, 62:1195-1198 1754380 14644858 10.1136/ard.2003.009589
29. Burmester GR Saez IM Malaise MG Kary S Kupper H Adalimumab (HUMIRA®) is effective and safe in treating rheumatoid arthritis (RA) in real-life clinical practice: 1-year-results of the ReAct study Arthritis Rheum 2005, 52(Suppl):S541-S542
30. Keystone EC Kavanaugh AF Sharp JT Tannenbaum H Hua Y Teoh LS Fischkoff SA Chartash EK Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial Arthritis Rheum 2004, 50:1400-1411 10.1002/art.20217 15146409
31. Furst DE Schiff MH Fleischmann RM Strand V Birbara CA Compagnone D Fischkoff SA Chartash EK Adalimumab, a fully human anti tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) J Rheumatol 2003, 30:2563-2571 14719195
32. Lipsky PE van der Heijde DM St Clair EW Furst DE Breedveld FC Kalden JR Smolen JS Weisman M Emery P Feldmann M Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group N Engl J Med 2000, 343:1594-1602 10.1056/NEJM200011303432202 11096166
33. van de Putte LB Rau R Breedveld FC Kalden JR Malaise MG van Riel PL Schattenkirchner M Emery P Burmester GR Zeidler H Efficacy and safety of the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: A 12 week, phase II study Ann Rheum Dis 2003, 62:1168-1177 1754401 14644854 10.1136/ard.2003.009563
34. Weinblatt ME Keystone EC Furst DE Moreland LW Weisman MH Birbara CA Teoh LA Fischkoff SA Chartash EK Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial Arthritis Rheum 2003, 48:35-45 10.1002/art.10697 12528101
35. Gomez-Reino JJ Carmona L Valverde VR Mola EM Montero MD Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report Arthritis Rheum 2003, 48:2122-2127 10.1002/ art.11137 12905464
36. Kroesen S Widmer AF Tyndall A Hasler P Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-α therapy Rheumatology (Oxford) 2003, 42:617-621 10.1093/rheumatology/keg263 12709536
37. Wallis RS Broder MS Wong JY Hanson ME Beenhouwer DO Granulomatous infectious diseases associated with tumor necrosis factor antagonists Clin Infect Dis 2004, 38:1261-1265 10.1086/383317 15127338
38. Bongartz T Sutton AJ Sweeting MJ Buchan I Matteson EL Montori V Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials JAMA 2006, 295:2275-2285 10.1001/jama.295.19.2275 16705109
39. Erhardt CC Mumford PA Venables PJ Maini RN Factors predicting a poor life prognosis in rheumatoid arthritis: An eight year prospective study Ann Rheum Dis 1989, 48:7-13 1003667 2923507
40. Prior P Symmons DP Scott DL Brown R Hawkins CF Cause of death in rheumatoid arthritis Br J Rheumatol 1984, 23:92-99 10.1093/rheumatology/ 23.2.92 6722416
41. Wolfe F Mitchell DM Sibley JT Fries JF Bloch DA Williams CA Spitz PW Haga M Kleinheksel SM Cathey MA The mortality of rheumatoid arthritis Arthritis Rheum 1994, 37:481-494 10.1002/art.1780370408 8147925
42. Askling J Fored CM Baecklund E Brandt L Backlin C Ekbom A Sundstrom C Bertilsson L Coster L Geborek P Haematopoietic malignancies in rheumatoid arthritis: Lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists Ann Rheum Dis 2005, 64:1414-1420 10.1136/ard.2004.033241 15843454
43. Askling J Fored CM Brandt L Baecklund E Bertilsson L Feltelius N Coster L Geborek P Jacobsson LT Lindblad S Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists Ann Rheum Dis 2005, 64:1421-1426 10.1136/ ard.2004.033993 15829572
44. Kapetanovic MC Geborek P Saxne T Larsson L Kristensen LE Svenson M Bendtzen K Development of antibodies against infliximab during infliximab treatment in rheumatoid arthritis. Relation to infusion reactions and treatment response Arthritis Rheum 2005, 52(Suppl):S543
45. Bartelds GM Wijbrandts CA Nurmohamed MT Stapel S Lems WF Aarden L Dijkmans BA Tak P Wolbink GJ Clinical response to adalimumab: The relationship with anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis Ann Rheum Dis 2007 17301106
46. Klareskog L Wajdula J Yeh P Fatenejad S Low autoantibody and anti-etanercept antibody formation and lack of impact on clinical outcomes following 5 years of treatment with Enbrel® in patients with rheumatoid arthritis Arthritis Rheum 2005, 52(Suppl):S348
47. Rat AC Boissier MC Rheumatoid arthritis: Direct and indirect costs Joint Bone Spine 2004, 71:518-524 10.1016/j.jbspin.2004.01.003 15589432
48. Van den Hout WB Goekoop-Ruiterman YPM Allaart CF De Vries-Bouwstra JK Van Zeben D Hazes JMW Kerstens P Breedveld FC Dijkmans BAC Additional costs of initial therapy including infliximab (IFX) in patients with early rheumatoid arthritis (RA) may be compensated by the value of sustained working hours: 2 year results of the best study Arthritis Rheum 2006, 54(Suppl):S227-S228
49. Cooper NJ Mugford M Symmons DP Barrett EM Scott DG Total costs and predictors of costs in individuals with early inflammatory polyarthritis: A community-based prospective study Rheumatology (Oxford) 2002, 41:767-774 10.1093/rheumatology/41.7.767 12096226
50. Bejarano V Quinn M Conaghan PG Keenan AM Reece RJ Walker D Gough AK Emery P Adalimumab plus methotrexate improves work stability and reduces job loss in early rheumatoid arthritis (RA): Results of the prevention of work disability (PROWD) study Arthritis Rheum 2006, 54(Suppl):4037-4038
51. Quinn MA Conaghan PG O'Connor PJ Karim Z Greenstein A Brown A Brown C Fraser A Jarret S Emery P Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial Arthritis Rheum 2005, 52:27-35 10.1002/art.20712 15641102
52. Goekoop-Ruiterman YP de Vries-Bouwstra JK Allaart CF van Zeben D Kerstens PJ Hazes JM Zwinderman AH Ronday HK Han KH Westedt ML Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial Arthritis Rheum 2005, 52:3381-3390 10.1002/art.21405 16258899
53. Green M Marzo-Ortega H McGonagle D Wakefield R Proudman S Conaghan P Gooi J Emery P Persistence of mild, early inflammatory arthritis: The importance of disease duration, rheumatoid factor, and the shared epitope Arthritis Rheum 1999, 42:2184-2188 10.1002/ 1529-0131(199910)42:10<2184::AID-ANR20>3.0.CO;2-2 10524691
54. van Dongen H van Aken J Lard L Visser K Ronday H Hulsmans H Speyer I Westedt M Peeters A Allaart C A double-blind randomized clinical trial in patients with undifferentiated arthritis: The Pro bable rheumatoid arthritis: Methotrexate versus Placebo Treatment (the PROMPT) - study Arthritis Rheum 2007, 56:1424-1432 10.1002/art.22525 17469099
55. Visser H le Cessie S Vos K Breedveld FC Hazes JM How to diagnose rheumatoid arthritis early: A prediction model for persistent (erosive) arthritis Arthritis Rheum 2002, 46:357-365 10.1002/art.10117 11840437
56. Conaghan PG McQueen FM Peterfy CG Lassere MN Ejbjerg B Bird P O'Connor PJ Haavardsholm E Edmonds JP Emery P The evidence for magnetic resonance imaging as an outcome measure in proof-of-concept rheumatoid arthritis studies J Rheumatol 2005, 32:2465-2469 16331788
57. Wakefield RJ Gibbon WW Conaghan PG O'Connor P McGonagle D Pease C Green MJ Veale DJ Isaacs JD Emery P The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: A comparison with conventional radiography Arthritis Rheum 2000, 43:2762-2770 10.1002/ 1529-0131(200012)43:12<2762::AID-ANR16>3.0.CO;2-# 11145034
58. van der Helm-van Mil AHM Verpoort KN Breedveld FC Huizinga TWJ Toes REM de Vries RRP The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis Arthritis Rheum 2006, 54:1117-1121 10.1002/art.21739 16572446
59. Hinks A Worthington J Thomson W The association of PTPN22 with rheumatoid arthritis and juvenile idiopathic arthritis Rheumatology (Oxford) 2006, 45:365-368 10.1093/rheumatology/kel005 16418195